Healthcare distributor and services company McKesson (NYSE: MCK) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 11.4% year on year to $106.2 billion. Its non-GAAP profit of $9.34 per share was 0.7% above analysts’ consensus estimates.

Is now the time to buy MCK? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

McKesson’s fourth-quarter results met Wall Street’s revenue expectations and modestly exceeded consensus for non-GAAP earnings per share, with the market responding positively. Management attributed the growth to robust performance in oncology, expanded biopharma services, and continued momentum in North American pharmaceutical distribution. CEO Brian Tyler specifically highlighted the integration of recent acquisitions such as Florida Cancer Specialists and Prism Vision as meaningful contributors. The company also cited the impact of technology investments, which improved workflow efficiency and productivity across segments.

Management raised its full-year non-GAAP earnings outlook, reflecting confidence in sustained growth across core business lines. Key drivers of the guidance include ongoing expansion in the oncology and multispecialty platforms, further automation to streamline operations, and scaling digital access solutions in biopharma services. CFO Britt Vitalone cautioned that while technology investments are expected to yield further efficiency gains, quarterly results may fluctuate due to drug launch timing and regulatory changes. Tyler emphasized, “We remain confident in our ability to execute on the planned separation, accelerate growth across our differentiated platforms, and maximize shareholder value.”

Key Insights from Management’s Remarks

Management cited oncology and multispecialty segment growth, successful technology integration, and strategic portfolio actions as central to the company’s recent performance.

• Oncology platform momentum: Growth in oncology and multispecialty services was driven by expanded provider networks, integration of Florida Cancer Specialists and Prism Vision, and a strong pipeline of new drug therapies. Management noted these additions expanded the company’s reach and service capabilities for community-based cancer care.
• Biopharma services expansion: The company launched 50 new programs across 43 brands in its biopharma access and affordability solutions, underscoring continued demand for streamlined patient support and medication access. These services are increasingly digitized, accelerating patient enrollment and improving affordability.
• Operational efficiency through technology: Investments in automation and artificial intelligence (AI) improved customer service and internal workflows. For example, electronic patient enrollment for specialty medications now occurs in minutes rather than days, while AI-powered customer support tools resolved most inquiries without escalation, enhancing productivity.
• Portfolio streamlining: McKesson completed its exit from European operations, including the divestiture of its Norway business, and advanced separation plans for its medical-surgical business. These actions are intended to sharpen strategic focus on core North American and specialty segments.
• Stable North American distribution: The North American pharmaceutical segment saw continued growth from specialty drugs, including GLP-1 medications, and stable prescription volumes from retail and health system customers. Management highlighted the importance of long-standing manufacturer partnerships in navigating evolving market and policy dynamics.

Drivers of Future Performance

McKesson’s outlook centers on oncology and biopharma services growth, ongoing technology investment, and active portfolio management amid regulatory complexity.

• Oncology and specialty acceleration: Management expects continued expansion in oncology and multispecialty, supported by organic provider growth and accretive acquisitions. The company believes these platforms will benefit from increasing demand for complex therapies and precision medicine, as well as enhanced operational scale.
• Technology-driven margin gains: Automation and AI remain priority investment areas, with anticipated benefits including higher productivity and improved operating margins, particularly in prescription technology solutions. Management stated that digital access solutions and workflow enhancements will be key to sustaining growth and efficiency.
• Regulatory and market headwinds: The company is closely monitoring U.S. healthcare policy shifts, including the Inflation Reduction Act’s Medicare Part D changes and broader pricing reforms. While management views the current landscape as navigable, it recognizes that policy changes, drug launch timing, and illness season variability could impact results from quarter to quarter.

Catalysts in Upcoming Quarters

Looking ahead, our analysts will be tracking (1) the pace of provider network expansion and integration within oncology and multispecialty, (2) measurable productivity improvements and margin gains from automation and AI-driven initiatives, and (3) the progress of the medical-surgical business separation. Shifts in U.S. healthcare policy and the adoption of new specialty therapies will also be important indicators.

McKesson currently trades at $836, up from $822 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.